[Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China].

Lung cancer is the malignant tumor with the highest incidence and mortality rate in China, among which non-small cell lung cancer (NSCLC) accounts for about 85%. BRAF mutation occurs about 1.5% to 5.5% in NSCLC patients, while BRAF V600 accounts for about 30% to 50% of all BRAF mutations. The overall prognosis of patients with BRAF-mutation is poor. At present, there are many clinical trials on BRAF-mutation NSCLC and new drugs constantly emerging. However, there is no standardized consensus on the diagnosis and treatment of BRAF-mutation NSCLC in China. The expert group of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association formulated this consensus by integrating foreign and domestic BRAF-mutation-related guidelines, consensus, and existing clinical trials, and combining with Chinese experts' clinical experience in the diagnosis and treatment of BRAF-mutation NSCLC. This consensus provides systematic recommendations for the clinical diagnosis and treatment process, rational drug choice, and adverse events management of BRAF-mutation NSCLC, aiming to provide reference for the standard of diagnosis and treatment of BRAF-mutation NSCLC.肺癌是中国发病率和死亡率均排第1位的恶性肿瘤，其中非小细胞肺癌(NSCLC)约占肺癌的85%。BRAF突变在NSCLC患者中的发生率约为1.5%~5.5%，而BRAF V600突变约占所有BRAF突变的30%~50%，BRAF突变患者整体预后较差。目前，关于BRAF突变NSCLC的临床研究探索越来越多，新药研发层出不穷，但国内尚无BRAF突变NSCLC诊疗相关的规范化共识。中国抗癌协会肺癌专业委员会专家组整合国内外BRAF突变相关的指南共识和现有的临床研究结果，结合我国BRAF突变的NSCLC诊疗经验，制定了中国晚期非小细胞肺癌BRAF突变诊疗专家共识，针对BRAF突变NSCLC的临床评估、诊疗流程、合理用药、不良反应管理等给出了详细建议，旨在为BRAF突变NSCLC的规范化管理和诊疗提供参考意见。.